All In Biotech

Drug Trial Radar · NCT02485067

Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB

Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study

Last checked: Nov 19, 2026Latest source record: Jan 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 384 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

384

Actual

Start

Jan 2015

Primary completion

Jul 2016

Study completion Sep 2016

Sponsor

Lead sponsor
SK Chemicals Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the efficacy and safety of THVD-201(Combination of tolterodine and pilocarpine) in patients with Overactive bladder during the period of treatment, 12 weeks. This study also includes an open label extension period of an additional 12 weeks following the treatment to assess long-term efficacy and safety of THVD-201 in patients with Overactive bladder.

Conditions

  • Overactive Bladder

Interventions

  • THVD-201Drug

    Combination of Tolterodine 2mg and Pilocarpine 9mg

  • Placebo(For THVD-201)Drug

  • Detrusitol 2mg tabletDrug

    Tolterodine 2mg

  • Placebo(For Detrusitol 2mg tablet)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean daily micturition frequencyTime frame: 12 weeks
  2. ADR Incidence of Dry mouthTime frame: 12 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Inje University Busan Paik Hospital

    Busan, South Korea

  • Dankook University Hospital

    Cheonan, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Pusan National University Hospital

    Pusan, South Korea

  • Bundang Cha Medical center

    Seongnam, South Korea

  • Ajou University Medical Center

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Cheil General Hospital

    Seoul, South Korea

  • Gachon University Gil Medical Center

    Seoul, South Korea

  • Konkuk University Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • The Catholic University of Korea, Bucheon ST. Mary's Hospital

    Seoul, South Korea

  • The Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.